Nous connaissons l'importance des impératifs de nos clients lors du développement de formulations solides, afin de produire un médicament biodisponible et stable. Notre gamme d'outils d'analyse complémentaire est conçue pour vous aider à économiser du temps et de l'argent en sélectionnant et en perfectionnant une forme de dosage optimale.

Nous visons à aider nos clients en proposant une gamme de techniques d'analyse utilisables pour étudier un large éventail de mécanismes d'administration du médicament :

  • Formulations de dosages solides (comprimé, capsules à effet immédiat ou prolongé),
  • Formulations semi-solides pour administration orale (sirops, suspensions),
  • Formulations de dosage liquides stériles (ophtalmologie, voie orale),
  • Injectables (injectables intraveineux, intramusculaires, sous-cutanés),
  • Médicaments par voie orale et nasale (vaporisateurs par voie nasale, inhalateurs de poudre sèche, inhalateurs doseurs, nébuliseurs)
  • Formulations à usage topique (crèmes, gels).


Nous proposons un service unique excellant dans la compréhension de l'interopérabilité des méthodes complémentaires disponibles en matière de taille ou forme des particules, charge de surface ou de mesures d'identification chimique ou de rhéologie.

Les outils de développement de formulations proposés par Malvern vous aideront à évaluer la biodisponibilité, la processabilité, la stabilité et l'uniformité de contenu de la formulation que vous envisagez de développer.

Drug product formulation

Development of a successful pharmaceutical formulation requires the combination of the active pharmaceutical ingredient (API) with inactive excipients. Excipients may be simple bulking agents, designed to aid control of the dose content uniformity. Increasingly, though, some excipients have a functional role in controlling drug release or ensuring the drug reaches the desired site of action. Here, compatibility between the selected excipient and the drug substance is critical in ensuring the correct dose is delivered within the required therapeutic window. Physicochemical analysis can aid excipient selection, enable the stability of the drug substance and drug product to be assessed, and also ensure the critical material attributes (CMAs) relating to formulation performance are identified as part of the design space definition applied for downstream manufacturing controls.

The Zetasizer Ultra can characterize the stability and quality of dispersions, emulsions and creams, reducing formulation time and speeding new products to market.

Complex formulations

The increasingly complex requirements for achieving reproducible drug delivery are a common challenge for formulation development scientists. Many new active pharmaceutical ingredients (APIs) are poorly soluble, meaning that traditional oral solid dose delivery is no longer relevant. Formulation complexity is therefore increasing, either to enable increased bioavailability for oral administration, or to enable local delivery so that the drug concentration at the site of action meets therapeutic requirements. 

Novel drug delivery systems, based on liposomes or other nanoparticle delivery systems, are being utilized more frequently to improve drug targeting. Malvern Panalytical’s range of complementary analysis techniques enables formulation developers to understand API and excipient formulation and stability. This aids the optimization of complex formulations, saving time in selecting an effective candidate formulation.

Complex generics

The challenges of developing complex formulations also extend to the development of generic drug products. Regulators around the world have recognized the impact of a lack of successful complex generic product introductions on healthcare costs. In response, they have released product-specific guidance which highlights the role of assessing physicochemical, or Q3, equivalence as part of the evaluation of the bioequivalence of a test generic product compared with a reference listed drug (RLD) product. 

Application of an in vitro bioequivalence testing approach has the potential to significantly reduce the time to market for new generics by removing the need for clinical endpoint studies. Malvern Panalytical’s toolkit of physicochemical analysis techniques and expertise which enables assessment of the properties of both the drug and the drug product formulation has a critical role to play in enabling successful in vitro bioequivalence studies.

Pharmaceutical Deformulation and Root Cause Analysis

Development of a sucessful generic formulation starts with an understanding of the structure and performance of the reference listed drug (RLD) product. Here, as in in vitro bioequivalence assessments, physicochemical analysis has an important role to play in advancing the understanding of pharmaceutical formulation requirements. Proactive, quantative, structural and morphological characterization of the API and excipients present within the RLD product can prototype formulation optimization and  significantly reduce development risks.

The benefits of this deformulation approach are not limited to generics companies. Similar methods are also applied in the development and manufacture of new drug products, providing insight to help pinpoint the root cause of changes in formulation performance during scale-up. It can also aid companies in understanding the impact of post-marketing changes to the manufacturing process or manufacturing location on the performance of a drug product.

The Morphologi 4-ID can be used to simplify and solve deformulation challenges and help establish in vitro bioequivalence. It can also be used to detect anomalies, contaminants and pinpoint process deviations during manufacturing.

Our solutions

Expert solutions in formulation et développement pharmaceutiques. Contact us to discuss your challenges.
Contact commercial Enregistrez vous maintenant